Xconomy Boston — After joining AstraZeneca’s Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and cardiovascular diseases.
Under the collaboration, expected to last multiple years, Gatehouse will use its sRNAlytics platform to identify small RNA (sRNA) signatures, which the company says help in diagnosing and subtyping diseases from human samples. Financial terms were not disclosed.
{iframe}https://xconomy.com/boston/2019/12/09/astrazeneca-taps-gatehouse-bio-to-identify-potential-drug-targets/?utm_source=Xconomy&utm_campaign=bc29d0aca1-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-bc29d0aca1-288460969&mc_cid=bc29d0aca1&mc_eid=7fe06a878f{/iframe}